| Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19) | European journal of cancer |  | | 2026 | 14 | 91 |
|
| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology | | | 2025 | 71 | 112 |
|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | | 2024 | 119 | 246 |
|
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | | 2023 | 132 | 183 |
|
| Unexpected impairment of INa underpins reentrant arrhythmias in a knock-in swine model of Timothy syndrome | Nature cardiovascular research | | | 2023 | 105 | 99 |
|
| Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing | European thyroid journal | | | 2023 | 222 | 782 |
|
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | | 2022 | 100 | 210 |
|
| Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study | Lung cancer | | | 2022 | 235 | 315 |
|
| Long-term follow-up for childhood cancer survivors: the Geneva experience | Swiss medical weekly | | | 2022 | 218 | 177 |
|
| Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? | Cancer treatment reviews | | | 2021 | 82 | 320 |
|
| Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study | Clinical Microbiology and Infection | | | 2019 | 269 | 236 |
|
| Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma | | | | 2019 | 554 | 745 |
|
| Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma | Digestive and Liver Disease |  | | 2017 | 560 | 1 |
|
| Les malades d'une unité de soins de support oncologiques | Revue médicale suisse | | | 2017 | 376 | 199 |
|
| Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer | Digestive and Liver Disease | | | 2017 | 537 | 0 |
|
| Multiple palpebral syringomas occurring after initiation of BRAF inhibition therapy in a patient with metastatic melanoma | JAAD case reports | | | 2016 | 514 | 169 |
|
| Chimiothérapie de maintenance : futile ou utile ? | Revue médicale suisse | | | 2015 | 496 | 253 |
|
| A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) | 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) | | | 2015 | 11 | 52 |
|
